Evidence map›Paper›PMID 26786981›Full record

ArticleJournal of Crohn's & colitis2016

Galectin-3 Plays an Important Pro-inflammatory Role in the Induction Phase of Acute Colitis by Promoting Activation of NLRP3 Inflammasome and Production of IL-1β in Macrophages.

Bojana Simovic Markovic, Aleksandar Nikolic, Marina Gazdic, Sanja Bojic, Ljubica Vucicevic, Milica Kosic, Slobodanka Mitrovic, Milos Milosavljevic, Gurdyal Besra, Vladimir Trajkovic and 3 more

Open access · bronzeAbstract read
In one paragraph

Article in Journal of Crohn's & colitis, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 70 papers.

0numbers the graph read from it
0cells of the map it votes in
70citing papers in PubMed
5.4field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

70 citing papers in PubMed, 129 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Article
  6. Review
  7. Article
  8. Article
  9. Review
  10. Review
  11. Article
  12. Review
  13. Review
  14. Review
  15. Article
  16. Dichotomous effects of Galectin-9 in disease modulation in murine models of inflammatory bowel disease.Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · 2025
    Article
  17. Article
  18. Article
  19. Article
  20. Article

10 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 4 institutions in 2 countries.

Bojana Simovic MarkovicCenter for Molecular Medicine and Stem Cell Research, Faculty of Medical Sciences, University of Kragujevac, Kragujevac, Serbia.
Aleksandar NikolicCenter for Molecular Medicine and Stem Cell Research, Faculty of Medical Sciences, University of Kragujevac, Kragujevac, Serbia.
Marina GazdicCenter for Molecular Medicine and Stem Cell Research, Faculty of Medical Sciences, University of Kragujevac, Kragujevac, Serbia.
Sanja BojicCenter for Molecular Medicine and Stem Cell Research, Faculty of Medical Sciences, University of Kragujevac, Kragujevac, Serbia.
Ljubica VucicevicInstitute of Microbiology and Immunology, School of Medicine, University of Belgrade, Belgrade, Serbia.
Milica KosicInstitute of Microbiology and Immunology, School of Medicine, University of Belgrade, Belgrade, Serbia.
Slobodanka MitrovicDepartment of Pathology, Faculty of Medical Sciences, Clinical Center Kragujevac, Kragujevac, Serbia.
Milos MilosavljevicDepartment of Pathology, Faculty of Medical Sciences, Clinical Center Kragujevac, Kragujevac, Serbia.
Gurdyal BesraInstitute of Microbiology and Infection, School of Biosciences, University of Birmingham, Birmingham, UK.
Vladimir TrajkovicInstitute of Microbiology and Immunology, School of Medicine, University of Belgrade, Belgrade, Serbia.
Nebojsa ArsenijevicCenter for Molecular Medicine and Stem Cell Research, Faculty of Medical Sciences, University of Kragujevac, Kragujevac, Serbia.
Miodrag L LukicCenter for Molecular Medicine and Stem Cell Research, Faculty of Medical Sciences, University of Kragujevac, Kragujevac, Serbia miodrag.lukic@medf.kg.ac.rs.
Vladislav VolarevicCenter for Molecular Medicine and Stem Cell Research, Faculty of Medical Sciences, University of Kragujevac, Kragujevac, Serbia.
University of Kragujevac · RSUniversity of Belgrade · RSClinical Centre of Kragujevac · RSUniversity of Birmingham · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND AND

aimsGalectin-3 [Gal-3] is an endogenous lectin with a broad spectrum of immunoregulatory effects: it plays an important role in autoimmune/inflammatory and malignant diseases, but the precise role of Gal-3 in pathogenesis of ulcerative colitis is still unknown.

methodsWe used a model of dextran sulphate sodium [DSS]-induced acute colitis. The role of Gal-3 in pathogenesis of this disease was tested by evaluating disease development in Gal-3 deficient mice and administration of Gal-3 inhibitor. Disease was monitored by clinical, histological, histochemical, and immunophenotypic investigations. Adoptive transfer was used to detect cellular events in pathogenesis.

resultsGenetic deletion or pharmacological inhibition of Gal-3 significantly attenuate DSS-induced colitis. Gal-3 deletion suppresses production of pro-inflammatory cytokines in colonic macrophages and favours their alternative activation, as well as significantly reducing activation of NOD-like receptor family, pyrin domain containing 3 [NLRP3] inflammasome in macrophages. Peritoneal macrophages isolated from untreated Gal-3(-/-) mice and treated in vitro with bacterial lipopolysaccharide or DSS produce lower amounts of tumour necrosis factor alpha [TNF-α] and interleukin beta [IL-1β] when compared with wild type [WT] cells. Genetic deletion of Gal-3 did not directly affect total neutrophils, inflammatory dendritic cells [DCs] or natural killer [NK] T cells. However, the total number of CD11c+ CD80+ DCs which produce pro-inflammatory cytokines, as well as TNF-α and IL-1β producing CD45+ CD11c- Ly6G+ neutrophils were significantly lower in colons of Gal-3(-/-) DSS-treated mice. Adoptive transfer of WT macrophages significantly enhanced the severity of disease in Gal-3(-/-) mice.

conclusionsGal-3 expression promotes acute DSS-induced colitis and plays an important pro-inflammatory role in the induction phase of colitis by promoting the activation of NLRP3 inflammasome and production of IL-1β in macrophages.

Indexed as

Acute DiseaseAnimalsBiomarkersCase-Control StudiesColitisColitis, UlcerativeColonCytokinesDextran SulfateFlow CytometryGalectin 3HumansInflammasomesInterleukin-1betaMacrophagesMaleBiomarkersCytokinesDextran SulfateGalectin 3InflammasomesInterleukin-1betaNLR Family, Pyrin Domain-Containing 3 ProteinNlrp3 protein, mouseDSS colitisGal-3NLRP3

Identifiers

PMID26786981
PMCPMC4957458
OpenAlexW2281484774

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.